Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
JINS HOLDINGS Inc. (3046.T)
JPY6,030.00
-210.00 (-3.37%)
JP JPX Healthcare Medical - Instruments & Supplies
Address
Iidabashi Grand Bloom 102-0071
Tokyo, JP
Tokyo, JP
CEO
Hitoshi Tanaka
Website
jinsholdings.com/jp
IPO
2008-09-05
ISIN JP3386110005
Also trades on
Other OTC · JNDOF (USD)
Tokyo Stock Exchange · 3046.T (JPY)
Description
JINS HOLDINGS Inc. is a Japanese corporation, operating through its subsidiaries, primarily involved in the design, manufacturing, wholesale, and retail of optical products and various fashion accessories. Its product portfolio includes a range of eyeglasses and lenses, alongside its innovative JINS MEME line, which allows users to monitor their physical and mental well-being. Beyond its core optical business, the firm also provides a selection of accessories for both genders, encompassing items like bags and headwear. Furthermore, it holds interests in agricultural contracting. JINS HOLDINGS maintains a global retail presence, with stores operating across Japan, mainland China, the U.S., Taiwan, and Hong Kong. Established in Tokyo, Japan, in 1988, the company operated as JINS Inc. until July 2019, when it adopted its current designation, JINS HOLDINGS Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY6,030.00
-210.00 (-3.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
288.2K
Beta
0.34
Float Shares
11.81M
Free Float %
50.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.38% | +7.83% | +24.59% | +55.26% | +34.75% | +50.18% | -3.05% | +170.82% | +3.12% | +122.34% | +9,504.65% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6,030.00
DCF (Unlevered)
13,549.39
+124.7%
DCF (Levered)
17,802.87
+195.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | +1 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.62
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+17.1% ★ Q2'26: +21.0% (vs Q2'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+86.9% ★ Q2'26: +13.9% (vs Q2'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+8.5% Q2'26: +0.0% (vs Q2'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+12.4% Q2'26: +13.4% (vs Q2'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+30.9% ★ Q2'26: +34.5% (vs Q2'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-4.5% ★ Q2'26: +0.0% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.55× ★ Q2'26: 0.37× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Aug 2015 actual |
Aug 2016 actual |
Aug 2017 actual |
Aug 2018 actual |
Aug 2019 actual |
Aug 2020 actual |
Aug 2021 actual |
Aug 2022 actual |
Aug 2023 actual |
Aug 2024 actual |
Aug 2025 actual |
Aug 2026 9 Rev. Ana. 9 EPS Ana. |
Aug 2027 9 Rev. Ana. 9 EPS Ana. |
Aug 2028 8 Rev. Ana. 8 EPS Ana. |
Aug 2029 7 Rev. Ana. 6 EPS Ana. |
Aug 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
40.70B
est: 40.70B (+0.0%)
|
46.19B
est: 46.96B (-1.6%)
|
50.45B
est: 50.90B (-0.9%)
|
54.87B
est: 54.77B (+0.2%)
|
61.89B
est: 62.12B (-0.4%)
|
60.26B
est: 59.73B (+0.9%)
|
63.90B
est: 64.77B (-1.3%)
|
66.90B
est: 66.96B (-0.1%)
|
73.26B
est: 73.73B (-0.6%)
|
83.00B
est: 82.23B (+0.9%)
|
97.22B
est: 96.25B (+1.0%)
|
110.98B
109.43B – 113.63B
+15.3% YoY
|
123.30B
118.81B – 129.19B
+11.1% YoY
|
133.45B
133.12B – 133.77B
+8.2% YoY
|
143.80B
140.09B – 149.04B
+7.8% YoY
|
155.00B
151.00B – 160.65B
+7.8% YoY
|
| EBITDA |
5.43B
est: 4.14B (+31.1%)
|
5.84B
est: 4.78B (+22.3%)
|
7.62B
est: 5.18B (+47.1%)
|
8.44B
est: 5.57B (+51.5%)
|
9.99B
est: 6.32B (+58.0%)
|
9.08B
est: 6.08B (+49.4%)
|
7.75B
est: 6.59B (+17.5%)
|
6.27B
est: 6.81B (-8.0%)
|
7.77B
est: 7.50B (+3.5%)
|
10.76B
est: 9.95B (+8.1%)
|
15.04B
est: 11.65B (+29.1%)
|
13.43B
13.25B – 13.75B
+15.3% YoY
|
14.93B
14.38B – 15.64B
+11.1% YoY
|
16.15B
16.11B – 16.19B
+8.2% YoY
|
17.41B
16.96B – 18.04B
+7.8% YoY
|
18.76B
18.28B – 19.45B
+7.8% YoY
|
| EBIT |
3.58B
est: 2.44B (+46.5%)
|
3.65B
est: 2.82B (+29.5%)
|
5.37B
est: 3.05B (+75.9%)
|
6.04B
est: 3.28B (+83.8%)
|
7.42B
est: 3.73B (+99.3%)
|
6.22B
est: 3.58B (+73.6%)
|
5.05B
est: 3.88B (+30.0%)
|
3.32B
est: 4.02B (-17.4%)
|
4.85B
est: 4.42B (+9.6%)
|
7.84B
est: 6.80B (+15.2%)
|
12.10B
est: 7.96B (+51.9%)
|
9.18B
9.05B – 9.40B
+15.3% YoY
|
10.20B
9.83B – 10.69B
+11.1% YoY
|
11.04B
11.01B – 11.07B
+8.2% YoY
|
11.89B
11.59B – 12.33B
+7.8% YoY
|
12.82B
12.49B – 13.29B
+7.8% YoY
|
| Net Income |
1.90B
est: 1.94B (-1.9%)
|
1.98B
est: 2.37B (-16.3%)
|
2.77B
est: 3.34B (-17.1%)
|
3.10B
est: 3.53B (-12.3%)
|
3.87B
est: 4.15B (-6.8%)
|
1.69B
est: 1.06B (+59.2%)
|
3.29B
est: 3.31B (-0.5%)
|
750.00M
est: 886.16M (-15.4%)
|
1.76B
est: 2.53B (-30.4%)
|
4.67B
est: 4.10B (+14.1%)
|
8.33B
est: 8.48B (-1.7%)
|
8.76B
8.50B – 9.06B
+3.4% YoY
|
9.89B
9.47B – 10.31B
+12.9% YoY
|
11.10B
10.47B – 11.95B
+12.2% YoY
|
11.90B
11.50B – 12.47B
+7.2% YoY
|
13.00B
12.57B – 13.62B
+9.2% YoY
|
| SGA |
24.89B
est: 26.73B (-6.9%)
|
28.68B
est: 30.84B (-7.0%)
|
30.32B
est: 33.43B (-9.3%)
|
33.02B
est: 35.97B (-8.2%)
|
37.27B
est: 40.80B (-8.7%)
|
38.03B
est: 39.23B (-3.1%)
|
42.29B
est: 42.54B (-0.6%)
|
45.70B
est: 43.98B (+3.9%)
|
48.44B
est: 48.43B (+0.0%)
|
53.59B
est: 53.89B (-0.6%)
|
60.74B
est: 63.07B (-3.7%)
|
72.72B
71.71B – 74.46B
+15.3% YoY
|
80.80B
77.85B – 84.66B
+11.1% YoY
|
87.45B
87.24B – 87.66B
+8.2% YoY
|
94.23B
91.80B – 97.67B
+7.8% YoY
|
101.57B
98.95B – 105.28B
+7.8% YoY
|
| EPS |
79.35
est: 79.35 (+0.0%)
|
82.58
est: 96.83 (-14.7%)
|
115.40
est: 136.67 (-15.6%)
|
129.17
est: 144.60 (-10.7%)
|
161.37
est: 169.97 (-5.1%)
|
71.47
est: 43.37 (+64.8%)
|
141.04
est: 135.39 (+4.2%)
|
32.13
est: 36.28 (-11.4%)
|
75.49
est: 104.96 (-28.1%)
|
200.13
est: 174.24 (+14.9%)
|
356.88
est: 350.74 (+1.8%)
|
375.21
364.05 – 388.09
+7.0% YoY
|
426.21
405.93 – 441.52
+13.6% YoY
|
480.06
448.48 – 512.02
+12.6% YoY
|
509.90
492.80 – 534.07
+6.2% YoY
|
557.00
538.33 – 583.40
+9.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.66B
OE per share TTM
69.73
Owner's Yield
0.86%
Maintenance CapEx ratio
24.67%
Maint CapEx / Avg PPE
14.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.47M
Shares Outstanding
23.35M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hitoshi Tanaka | Founder, Group CEO & Chairman | 269M | male |
| Ryo Tanaka | President, Executive Officer, COO & Representative Director | 132M | male |
| Ming-Chi Chiou | Managing Executive Officer | — | female |
| Motoaki Nakatani | Exe. Off., CFO, Head of Glob. All. & Strategy, and Head of IR Off. | — | — |
| Shingo Kobayashi | Executive Officer & Head of Philippines Business | — | — |
| Shinichiro Matsuda | Managing Executive Officer & Head of Technology | — | male |
| Yasuhiro Hayashi | Sr. Mng. Exe. Off. and Global Head of Sales, Operation & Digital | — | — |
| Hiroyuki Kondo | Exe. Off., Global Head of HR, Admin. & New Business | — | male |
| Yukinori Arakawa | Executive Officer & Asia Region CFO | — | male |
| Maki Ube | Managing Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3046.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
